trending Market Intelligence /marketintelligence/en/news-insights/trending/l5j9yhbrozwo7zel7_uufg2 content esgSubNav
In This List

Proteostasis plans common stock offering

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Proteostasis plans common stock offering

Proteostasis Therapeutics Inc. plans to sell 9 million common shares in an underwritten public offering

The company plans to grant the underwriters an option to buy up to an additional 15%, or 1,350,000 common shares, in the public offering.

Leerink Partners and RBC Capital Markets are acting as joint book-running managers, and H.C. Wainwright & Co. is acting as lead manager for the offering.